Big biotech's upcoming clinical priorities
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Biotech heads towards big catalysts
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
No Blys for Vera
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Ash 2022 preview – Novartis has Apellis in its sights
Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
The gloom deepens for biopharma stocks
With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.